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High mortality in tuberculosis patients despite HIV  
interventions in Swaziland
G. Mchunu,1 J. van Griensven,2 S. G. Hinderaker,3 W. Kizito,4 W. Sikhondze,1 M. Manzi,5  
T. Dlamini,1 A. D. Harries6,7
Tuberculosis (TB) remains a major global public health problem, annually affecting approximately 
9 million people and resulting in 1.5 million deaths. 
Most of the notified cases and reported deaths are 
from sub-Saharan Africa.1 Swaziland, a small southern 
African country, has one of the highest TB incidence 
rates globally and one of the highest generalised prev-
alences of human immunodeficiency virus (HIV) in 
the world, at 31% among persons aged 18–49 years.2 
According to the 2014 National TB Control Pro-
gramme (NTCP) report, 97% of TB patients were tested 
for HIV, of whom 73% were co-infected with HIV.3
HIV has been shown to be the single most import-
ant risk factor both for developing TB and for the asso-
ciation with poor TB outcomes, including high fatality 
rates.4,5 The use of highly active antiretroviral therapy 
(ART) has been shown to reduce the risk of acquiring 
TB by up to 70–90%.6 Furthermore, the combined use 
of cotrimoxazole preventive therapy (CPT) and ART 
has been shown to reduce mortality among TB-HIV 
co-infected individuals.7,8 CPT and ART have been 
proposed as part of the strategy to reduce the adverse 
outcomes among TB patients co-infected with HIV.6,7,9
Several studies have shown the impact of the initial 
scaling up of ART on TB case notification in southern 
Africa.10,11 Clear reductions in mortality among HIV 
co-infected patients have also been reported in associ-
ation with ART scale-up.7 However, in a recent study 
in Malawi, little additional progress in terms of mor-
tality and other adverse outcomes had been seen over 
the previous 4–5 years.7 One of the reasons could be 
that, despite substantial progress, complete national 
coverage of HIV services might be difficult to achieve 
in resource-constrained countries with relatively weak 
health systems. As such, the full impact of HIV service 
provision in national TB programmes might not have 
been realised in these settings.
In this respect, a country such as Swaziland is un-
usual. Swaziland has a high prevalence of TB and HIV,3 
it is a relatively small country and it is better resourced 
than many others, with a reasonably well functioning 
health care system. Universal ART coverage was re-
portedly achieved for the general HIV population in 
2011.12 However, this was not the case for the TB pa-
tients in our study.
The aim of this study was to describe the impact of 
HIV interventions on the trend of TB treatment out-
comes during 2010–2013 in Swaziland. Using aggre-
gate NTCP data, we describe the evolution in TB case 
notifications, the uptake of HIV testing and ART and 
CPT initiation and the proportion of TB-HIV co-in-
fected patients with adverse treatment outcomes, in-
cluding mortality, loss to follow-up and treatment 
failure.
METHODS
Study design
This was a retrospective descriptive study using rou-
tinely collected aggregated NTCP data.
Study setting
Swaziland, located in southern Africa, has a popula-
tion of approximately 1.1 million, of whom 70% live 
in rural areas.13 Although Swaziland is a low to mid-
dle-income country, more than 60% of the population 
lives below the poverty line.14 In 2014, the prevalence 
of TB was estimated to be 605 per 100 000 population, 
with an incidence that is among the highest in the 
world, at 733/100 000.15
Swaziland has a DOTS-based programme that ap-
plies all procedures, including case finding, registra-
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Setting: All health facilities providing tuberculosis (TB) 
care in Swaziland.
Objective: To describe the impact of human immunode-
ficiency virus (HIV) interventions on the trend of TB treat-
ment outcomes during 2010–2013 in Swaziland; and to 
describe the evolution in TB case notification, the uptake 
of HIV testing, antiretroviral therapy (ART) and cotrimox-
azole preventive therapy (CPT), and the proportion of 
TB-HIV co-infected patients with adverse treatment out-
comes, including mortality, loss to follow-up and treat-
ment failure.
Design: A retrospective descriptive study using aggre-
gated national TB programme data.
Results: Between 2010 and 2013, TB case notifications 
in Swaziland decreased by 40%, HIV testing increased 
from 86% to 96%, CPT uptake increased from 93% to 
99% and ART uptake among TB patients increased from 
35% to 75%. The TB-HIV co-infection rate remained 
around 70% and the proportion of TB-HIV cases with ad-
verse outcomes decreased from 36% to 30%. Mortality 
remained high, at 14–16%, over the study period, and 
anti-tuberculosis treatment failure rates were stable over 
time (5%).
Conclusion: Despite high CPT and ART uptake in TB-HIV 
patients, mortality remained high. Further studies are re-
quired to better define high-risk patient groups, under-
stand the reasons for death and design appropriate 
interventions.
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tion, diagnosis, treatment and treatment outcomes, in 
line with international guidelines.16 Xpert® MTB/RIF 
(Cepheid, Sunnyvale, CA, USA) was introduced for TB 
diagnosis in 2011 and adopted nationwide as an initial 
diagnostic test for all presumptive TB cases in 2012. 
Culture and drug susceptibility testing (DST) were per-
formed for specific indications, such as treatment fail-
ure, during the study period. The NTCP has provided 
treatment for multidrug-resistant TB (MDR-TB) since 
2006.17
The ART programme in Swaziland was launched in 
2003. Indications for ART follow World Health Organi-
zation (WHO) guidelines, and since 2010 a CD4 count 
threshold of 350 cells/μl has been used. As mentioned, 
universal ART coverage was achieved in 2011.12 In 
2006, the country adopted a partial TB-HIV services in-
tegrated model by which all TB patients are offered 
HIV testing and all HIV patients are screened for TB. 
All TB-HIV co-infected patients are initiated on CPT, 
and since 2008 all HIV-positive TB patients have been 
initiated on ART, regardless of their CD4 cell count, 
within 8 weeks of initiating anti-tuberculosis treat-
ment.18 During the study period, first-line ART for TB 
patients consisted of the combination of stavudine, 
lamivudine and efavirenz. Isoniazid preventive ther-
apy (IPT) has been recommended for HIV patients 
since 2007, but this has not been systematically and 
consistently implemented. At the primary health care 
level, TB and HIV services are co-localised under the 
same roof, whereas at higher levels these services are 
located on the same premises but in different 
departments.
Study population
The study population included all TB patients regis-
tered by the NTCP between 2010 and 2013. Cases with 
documented drug resistance were excluded, as notifica-
tion and reporting on treatment outcomes is per-
formed separately.
Data variables, source of data and analysis
The case finding and treatment outcome data for all 
TB patients are recorded with a unique identifier in the 
TB register. In terms of data collection and collation, 
the NTCP has a robust data verification system in 
which the regional levels validate and collate the 
health facility data, which are in turn transmitted to 
the central unit of the NTCP. The central unit con-
ducts quarterly onsite data verification to ascertain 
data quality assurance, performs analyses and trans-
mits the results to the WHO global reporting system 
annually. Quarterly review meetings are organised to 
provide a forum for feedback, peer review on findings 
of data quality assessments and discussions on correc-
tive actions for addressing gaps in data quality. In ad-
dition, Regional TB Coordinators provide quarterly 
support supervision to health facility staff.
For this study, we used aggregated data sourced 
from the NTCP reports. The following information was 
retrieved from the case finding report: year of enrol-
ment, number of patients enrolled nationally for an-
ti-tuberculosis treatment, HIV testing and results, initi-
ation of CPT and ART, and sex. Data variables for 
anti-tuberculosis treatment outcomes among those 
registered with TB-HIV included the number of TB-
HIV patients evaluated for final treatment outcomes 
among new and retreatment cases for all TB treatment 
categories. Adverse outcomes included death, loss to 
follow-up, treatment failure and not evaluated. (Loss 
to follow-up refers to what was previously reported as 
treatment default.19) Patients who miss appointments 
are contacted by phone and/or visited at home by ad-
herence officers, although the system was not univer-
sally functional at all treatment centres during the 
study period. Family treatment supporters, where 
available, provide directly observed treatment (DOT) 
for patients on anti-tuberculosis medications.
We used EpiData software for data entry (version 
3.1, EpiData Association, Odense, Denmark). All data 
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FIGURE 1 Trends in HIV testing and CPT and ART uptake amongst patients with TB 
in Swaziland, 2010–2013. HIV = human immunodeficiency virus; CPT = cotrimoxazole 
preventive therapy; ART = antiretroviral treatment; TB = tuberculosis.
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were independently validated by a second person. Data were then 
transferred to Excel software (Microsoft Corp, Redmond, WA, 
USA) for a descriptive analysis, presenting absolute numbers and 
proportions of HIV coinfection, uptake of CPT and ART, and ad-
verse treatment outcomes per year.
Ethics approval
Permission to carry out the study was obtained from the Swazi-
land Ministry of Health Scientific Research and Ethics Commit-
tee, Mbabane, Swaziland. The Médecins Sans Frontières Ethics Re-
view Board (Geneva, Switzerland) approved the criteria for studies 
of routinely collected data, and approval was also granted by the 
Ethics Advisory Group of the International Union Against Tuber-
culosis and Lung Disease, Paris, France. As this was a record re-
view study with aggregated anonymised data, the issue of in-
formed patient consent did not apply.
RESULTS
The number of TB cases notified between 2010 and 2013, along 
with the numbers of patients who were tested for HIV, tested 
HIV-positive, tested HIV-negative, started on CPT and on ART, are 
shown in Figure 1. There was a decrease of 40% in the number of 
patients enrolled for anti-tuberculosis treatment, from 11 057 
cases in 2010 to 6665 in 2013. The same trend was observed 
among HIV-positive patients with TB. HIV testing uptake in-
creased from 86% in 2010 to 96% in 2013. The coinfection rate 
remained stable, at around 70%. Over 90% of the patients were 
prescribed CPT over the time period, from 93% in 2010 to 99% in 
2013. ART uptake among TB-HIV co-infected patients increased 
from 35% to 75% over the study period.
Annual trends in adverse outcomes among TB-HIV patients are 
shown in Figure 2. The proportion with adverse outcomes 
amongst all notified TB-HIV patients decreased from 36% in 2010 
to 30% in 2013 (Figure 2A). Mortality remained high, at between 
14% and 16% over the study period notified. Failure rates were 
stable over time (5%). The proportion of loss to follow-up de-
creased from 11% in 2010 to 9% in 2013. Similarly, the propor-
tion without treatment outcome information declined from 7% 
in 2010 to 2% in 2013. Failure rates among retreatment patients 
were higher, ranging from 7% to 10% (Figure 2C). Apart from the 
higher mortality among TB retreatment cases in 2011, the trends 
were generally comparable between new and retreatment cases 
(Figure 2B and 2C).
DISCUSSION
We report on the impact of HIV interventions, which included 
high uptake of CPT and ART, on anti-tuberculosis treatment out-
comes in all TB-HIV co-infected patients in an African country 
with a reasonably well-functioning health care system. Between 
2010 and 2013, ART coverage among patients co-infected with 
TB-HIV increased substantially, reaching 75%. Across the same 
time period, a clear reduction in total and HIV-associated TB case 
notifications was observed, in line with other studies.7,10 Contrary 
to our expectations, the rate of mortality amongst TB-HIV pa-
tients did not decline but remained stable, at 14–16%, despite the 
high coverage of CPT and increasing ART uptake.
Our findings on the stable mortality rate are in line with a re-
cent study from Malawi where, despite an ART uptake of up to 
88%, no reduction in mortality among notified TB cases was seen 
between 2008 and 2012,7 but rather a trend towards higher mor-
tality, which reached 13–15%. The WHO and other international 
stakeholders have recently engaged to reduce TB mortality by 
90% by 2030.15 With 70% of the TB burden occurring in HIV-in-
fected patients in countries such as Swaziland, the high case fatal-
ity rates in TB-HIV coinfection seriously compromise the chances 
of achieving these targets.
Why do high numbers of TB-HIV patients still die despite in-
creasing ART coverage, and what can be done about it? Why was 
universal ART coverage not achieved in TB patients? We note a 
number of challenges in the NTP that could explain why univer-
sal ART coverage was not achieved for TB patients. First, the re-
sponsibility for ART initiation was confined to doctors during the 
study period. In addition, there was only partial integration of 
TB-HIV services and decentralisation was slow, which could have 
contributed to the high rates of loss to follow-up among TB-HIV 
co-infected patients. The separate monitoring and evaluation sys-
tems for the TB and HIV programmes possibly led to loss of data. 
Finally, while meetings of multidisciplinary teams were foreseen 
FIGURE 2 Adverse treatment outcomes amongst HIV-positive pa-
tients with TB in Swaziland, 2010–2013. A) All patients with TB; B) 
New patients with TB; C) Retreatment cases. Adverse treatment out-
comes include death, failure, loss to follow-up and not evaluated. 
Not evaluated refers to patients without outcome data available, in-
cluding those transferred out. TB = tuberculosis; HIV = human immu-
nodeficiency virus.
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to discuss and address common challenges in TB and HIV service 
delivery, these meetings were inconsistent. In response to this, 
task shifting of ART initiation to nurses has been undertaken, the 
decentralisation and integration of TB services has been en-
hanced, and mechanisms for better coordination of TB-HIV col-
laborative activities at all levels have been put in place.
The Table presents a number of key operational research ques-
tions that should follow this study. Who is missing out on ART in 
Swaziland, and when exactly is ART being initiated? A recent 
study from South Africa revealed that ART uptake was particularly 
low in individuals with very low CD4 counts, and that this group 
also had the highest mortality.20 Targeting this patient group 
would thus be a potential strategy to further reduce case fatality. 
This approach, however, requires CD4 testing to be available, and 
in the current climate where ‘HIV test and treat’ is now being rec-
ommended, widespread coverage with CD4 technology might be 
difficult. What is the cause of death in TB-HIV patients? In South 
Africa, it was recently found that only 34% of deaths at autopsy 
in TB-HIV patients could be attributed to TB.21 What is the role of 
non-communicable diseases, an emerging problem linked to 
TB?22,23 How good is adherence to TB and HIV treatment, and is 
quality assurance of anti-tuberculosis medications strictly 
maintained?
Ultimately, what is needed are effective tools for the identifica-
tion of TB-HIV patients at high risk for death that are linked to 
appropriate operational and clinical management strategies ad-
dressing co-morbidities beyond TB and HIV.
We also need more evidence on whether the effect on mortal-
ity of early ART initiation observed in clinical trials is confirmed 
in routine clinical settings. For such interventions, the 6-month 
follow-up period might be too short-term to reveal efficacy. In the 
CAMELIA trial in Cambodia, for example, the effect of early ART 
initiation was only apparent beyond 6 months after TB 
diagnosis.8,24
Pending further research, we need to strengthen a number of 
strategies that are likely to impact TB and HIV-related mortality 
and morbidity. The 90–90–90 treatment targets for HIV that have 
recently been proposed imply that, by 2020, 90% of individuals 
living with HIV have to be diagnosed and know their HIV status, 
90% of HIV-infected people have to be on ART, and 90% of these 
should have viral suppression.12,25 Effective implementation of 
this strategy would contribute to TB prevention in people living 
with HIV infection.4,25 In parallel, 100% ART uptake in TB pa-
tients should be prioritised. In addition, the introduction of cul-
ture and DST for all bacteriologically confirmed TB cases will 
facilitate early diagnosis of drug-resistant strains. This particular 
intervention was not implemented during the study period.
Systematic screening for TB with Xpert in HIV patients, com-
bined with the use of the urine lipoarabinomannan (LAM) assay, 
which shows higher sensitivity with lower CD4 counts, would en-
hance early TB diagnosis and might identify patients at higher 
risk for death.26–28 Increased uptake of IPT would further contrib-
ute to TB prevention in people living with HIV, and ultimately re-
duce TB-related mortality.29
MDR-TB is also an increasing problem in Swaziland and, par-
ticularly if not detected or detected late, is associated with adverse 
outcomes.30 A recent study in Swaziland found that, due to the 
prevalence of specific mutations in the rifampicin (RMP) gene, 
the sensitivity of Xpert to detect RMP resistance is reduced.31 In 
response to this, routine culture and DST have now been intro-
duced. The last MDR-TB prevalence survey dates from 2009; the 
planned drug resistance survey will give more insight into the 
current situation.
One of the strengths of this study is the use of national data 
that are representative of what is happening in the country. A 
fairly robust system for data validation was in place during the 
entire study period. Limitations include the fact that mortality is 
likely to be underestimated as deaths might have occurred in 
those lost to follow-up, transferred out or not evaluated.7 Conse-
quently, we cannot exclude the possibility that the improvements 
in outcome reporting over time—with decreasing proportions of 
patients lost to follow-up or who lacked outcome data—might 
have concealed a modest decline in mortality in our data. The use 
of aggregated data precluded more in-depth evaluation, for exam-
ple, on the timing of ART. Data on CD4 cell counts were also not 
available. One important limitation of the study is that TB-HIV 
data prior to 2010 were not available, hence the short proposed 
study period. In addition, we only had treatment outcomes for 
patients with HIV-associated TB; we did not have treatment out-
comes for patients with HIV-negative TB. TB treatment outcomes 
TABLE Priority operational research questions to address mortality in TB-HIV co-infected patients
TB-related HIV-related Other
• Does poor adherence to anti-tuberculosis 
treatment contribute to mortality?
• Does undetected TB drug resistance contribute 
to mortality?
• Do the anti-tuberculosis drugs being procured 
in Swaziland contain the correct amount of 
active drug?
• What are the factors contributing to delayed TB 
diagnosis?
• Which health facility factors are associated with 
effective TB-HIV integration and improved 
treatment outcomes? 
• What is the value of LAM urine screening to 
identify individuals at high risk of death?
• What is the cause of mortality and when do 
patients die? 
• What proportion of patients die from causes 
other than TB?
• Who are the patients not started on ART? Are 
there substantial delays in ART initiation and 
what are the causes?
• Does poor ART adherence and/or HIV drug 
resistance contribute to mortality?
• Does delayed CPT initiation and/or poor 
adherence contribute to mortality?
• What is the effect of ART on mortality beyond 
the 6-month follow-up period?
• What factors contribute to delayed HIV 
diagnosis and/or CPT/ART initiation?
• Is TB IRIS correctly diagnosed in routine 
clinical settings? How is it managed? What is 
the associated mortality rate?
• What is the proportion of patients who have 
died in transfers-out and patients with no 
treatment outcome information (not 
evaluated)?
• What other communicable and non-
communicable co-morbidities, such as diabetes 
mellitus, are prevalent in TB-HIV co-infected 
patients and do they influence mortality?
• How prevalent are macro- and micro-nutritional 
deficiencies, and what is the optimal nutritional 
support package?
TB = tuberculosis; HIV = human immunodeficiency virus; ART = antiretroviral therapy; CPT = cotrimoxazole preventive therapy; LAM = lipoarabinomannan assay; IRIS = im-
mune reconstitution inflammatory syndrome.
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for HIV-positive and HIV-negative patients could not therefore be 
compared.
In conclusion, this study revealed that, despite increasing ART 
coverage in TB patients, mortality remained high in TB-HIV co-in-
fected patients. Further studies are required to better define pa-
tient groups with a high risk for death, to understand the reasons 
for death and failure to start ART, and to design appropriate inter-
ventions. Reducing TB case fatality rates in HIV-infected patients 
will be vital to achieve the targeted 90% reduction in TB mortal-
ity within 15 years.
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Contexte  :  Toutes les structures de santé offrant une prise en charge 
de la tuberculose (TB) au Swaziland.
Objectif  :  Décrire l’impact des interventions pour le virus de 
l’immunodéficience humaine (VIH) sur les tendances des résultats du 
traitement de la TB en 2010–2013, au Swaziland. Décrire l’évolution 
de la notification des cas de TB, la couverture du test VIH, de le 
traitement antirétroviral (TAR) et du traitement préventif au 
cotrimoxazole (CPT) et la proportion de patients coinfectées par TB-
VIH avec les mauvais résultats du traitement incluant la mortalité, les 
abandons et les échecs du traitement.
Schéma  :  Etude descriptive rétrospective basée sur les données 
agrégées du programme national TB.
Résultats  :  Entre 2010 et 2013, les notifications de cas de TB au 
Swaziland ont diminué de 40%, le test VIH a augmenté de 86% à 
96%, la couverture du CPT a augmenté de 93% à 99% et la 
couverture du TAR parmi les patients tuberculeux est passée de 35% 
à 75%. Le taux de coinfection TB-VIH est resté autour de 70% et la 
proportion de cas de TB-VIH avec des résultats médiocres a diminué 
de 36% à 30% entre 2010 et 2013. La mortalité est restée élevée 
entre 14% et 16% pendant la période d’étude et les taux d’échec du 
traitement TB ont été stables dans le temps (5%).
Conclusion  :  En dépit d’une couverture élevée du CPT et du TAR 
parmi les patients TB-VIH, la mortalité est restée élevée. D’autres 
études sont nécessaires pour mieux définir les groupes de patients à 
haut risque, pour mieux comprendre les causes de décès et pour 
concevoir des interventions appropriées.
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Marco de referencia: Todos los establecimientos de salud que 
prestan atención antituberculosa en Swasilandia.
Objetivo: Describir la repercusión de las intervenciones contra el 
virus de la inmunodeficiencia humana (VIH) sobre la evolución de los 
desenlaces terapéuticos de la tuberculosis (TB) del 2010 al 2013 en 
Swasilandia. Describir la evolución de la notificación de casos de TB, 
la aceptación de la prueba diagnóstica del VIH, el tratamiento 
antirretrovírico (TAR) y del tratamiento preventivo con cotrimoxazol 
(CPT) y la proporción de pacientes coinfectados por el VIH y el bacilo 
de la TB que presenta desenlaces terapéuticos desfavorables como la 
mortalidad, la pérdida durante el seguimiento y el fracaso del 
tratamiento.
Método: Fue este un estudio descriptivo retrospectivo a partir de los 
datos agregados del Programa Nacional contra la TB.
Resultados: Del 2010 al 2013, la notificación de casos de TB en 
Swasilandia disminuyó un 40%, la aceptación de la prueba diagnóstica 
del VIH aumentó de 86% a 96%, la utilización del CPT aumentó del 
93% al 99% y en los pacientes con TB, y la aceptación del TAR aumentó 
del 35% al 75%. La tasa de coinfección permaneció alrededor del 70% 
y la proporción de estos pacientes que presentaba desenlaces 
desfavorables disminuyó del 36% en el 2010 al 30% en el 2013. 
Durante el período del estudio la mortalidad permaneció alta, entre el 
14% y 16%, y las tasas de fracaso del tratamiento antituberculoso 
permanecieron estables con el transcurso del tiempo (menos del 5%).
Conclusión: Pese a una alta aceptación del CPT y el TAR por parte de 
los pacientes coinfectados por el VIH y la TB, la mortalidad sigue 
siendo alta. Se precisan nuevos estudios que definan con mayor 
precisión los grupos de pacientes con alto riesgo de desenlaces 
desfavorables y que contribuyan a comprender las causas de las 
defunciones y a diseñar intervenciones apropiadas.
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